Zoetis Inc. (NYSE:ZTS) Shares Acquired by Catalyst Financial Partners LLC

Catalyst Financial Partners LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,047 shares of the company’s stock after acquiring an additional 101 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Zoetis were worth $404,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in ZTS. Verdence Capital Advisors LLC raised its holdings in Zoetis by 12.2% during the third quarter. Verdence Capital Advisors LLC now owns 2,791 shares of the company’s stock worth $486,000 after purchasing an additional 303 shares during the last quarter. Brighton Jones LLC boosted its position in shares of Zoetis by 9.3% in the 3rd quarter. Brighton Jones LLC now owns 2,783 shares of the company’s stock worth $484,000 after buying an additional 237 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Zoetis by 0.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 177,648 shares of the company’s stock valued at $30,938,000 after acquiring an additional 1,054 shares during the last quarter. NBT Bank N A NY purchased a new position in Zoetis during the 3rd quarter valued at about $1,832,000. Finally, Advisor Partners II LLC increased its holdings in Zoetis by 4.0% during the 3rd quarter. Advisor Partners II LLC now owns 24,068 shares of the company’s stock valued at $4,187,000 after acquiring an additional 922 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ZTS. Barclays dropped their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, The Goldman Sachs Group reduced their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $211.75.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 2,209 shares of company stock worth $371,293 over the last ninety days. 0.16% of the stock is owned by company insiders.

Zoetis Trading Down 2.1 %

ZTS traded down $3.53 during midday trading on Wednesday, hitting $164.92. The company’s stock had a trading volume of 4,669,191 shares, compared to its average volume of 3,195,939. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a 50-day moving average price of $167.64 and a two-hundred day moving average price of $178.93. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The firm has a market cap of $75.25 billion, a P/E ratio of 31.78, a PEG ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter last year, the business earned $1.31 EPS. Zoetis’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, research analysts anticipate that Zoetis Inc. will post 5.77 earnings per share for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.